Press Release
ARISE clinical study presented at the 31st Annual Meeting of the European Association For Cardio-Thoracic Surgery (EACTS) 2017 in Vienna
Brazilian group reports results of decellularised allografts used for RVOT construction during the ROSS operation
Training workshop for young surgeons held in Barcelona in November 2017
Prof. Dr. Samir Sarikouch presented the current status of the ARISE clinical study during a Focus Session on “Alternative surgical approaches for aortic valve replacement” at the 31st EACTS Meeting in Vienna, Austria on Tuesday 10th of October 2017. He gave an overview about the current inclusion to the clinical trial. So far, 99 patients have been operated within the trial. 14 more operations are already scheduled, which means that the calculated minimal sample size of 120 study participants can be safely achieved in 2018 well ahead of the study schedule.
During the same congress Prof. Francisco da Costa presented the results of “Fresh decellularized versus standard cryopreserved pulmonary allografts for RVOT reconstruction during the Ross operation” operated by his group from Curitiba, Brasil (Abstract No. 0349). He presented data of 190 decellularized allografts used for pulmonary valve replacement with a mean follow-up time of 3.7 ± 2.5 years. Freedom from late peak gradients ≥ 40 mmHg was significantly better for the dCell group (95.8%, CI 95% = 87.9 – 98.6%) than in the standard cryopreserved group (88.5%, CI95% = 82.6- 92.5%) at 10 years (p=0.04). He concluded that “although longer follow-up is still necessary, this study demonstrated that decellularized allografts have superior hemodynamic performance at 10 years when compared to conventional cryopreserved allografts”.
On Friday the 18th of November 28, 2017 the ARISE partners conducted a training workshop for young surgeons focusing on the techniques for the implantation of decellularized homografts for aortic valve replacement. Under the patronage of the former EACTS president Prof. Jose Luis Pomar the workshop was held at the Hospital Clinic Barcelona, Spain.
Programme:
08:30
Welcome and Introduction.
Dr. Axel Haverich and Dr. José L. Pomar
08:45
What is the H2020 program of the European Union?
Juan Abolafia
09:05
Why ARISE and ESPOIR got funding from the European Framework Programme.
Dr. Axel Haverich
09:30
Summarizing the goals and rationale of the ARISE Project.
Dr. Samir Sarikouch
09:45
The role of the European tissue banks.
Dr. Ramadan Jashari
10:15
Let us explain to you how this technique works:
a) The first human implantation of a decellularized homograft in the ARISE project – Live-In-A-Box case
Dr. Igor Tudorache
b) The first implantation in our hospital - Live-In-A-Box case
Dr. Eduard Quintana
10:45
How the Spanish and Catalan Transplantation Network could help to disseminate the project’s results.
Dr. Esteve Trias
11:00
Reimbursement of cell-free homografts beyond ARISE.
Dr. Michael Harder
11:15 Coffee break
11:45
Current outcomes of the ARISE project.
Dr. Samir Sarikouch
11:55
Current outcomes of the ESPOIR project.
Dr. Dietmar Böthig
12:05
Results from other researchers.
Dr. Samir Sarikouch
12:15
Reasons for concern? The Mayo Clinic report.
Dr. Axel Haverich
12:30
Let's go to practice! - Wetlab: Tips and tricks for the implantation of decellularized homografts. Animal hearts and Live-In-A-Box cases.
Dr. Daniel Pereda and Dr. Eduard Quintana
14:00 Lunch
15:00
Wetlab continuation.
17:30
Conclusions for the media.